What is the role of infliximab in the treatment of extrapulmonary sarcoidosis?

Updated: Sep 15, 2020
  • Author: Nader Kamangar, MD, FACP, FCCP, FCCM; Chief Editor: Zab Mosenifar, MD, FACP, FCCP  more...
  • Print

In addition, long-term treatment with infliximab can be effective for extrapulmonary sarcoidosis, according to a retrospective study of 26 patients with biopsy-proven sarcoidosis. [14] In the study, sustained resolution or improvement occurred in 58.5% of organs, but disease activity progressed in 5.7% despite treatment. In 57.7% of patients, there were adverse events during an average duration of therapy of 46.2 months. [14] Improvement in pulmonary imaging findings was observed in patients with pulmonary sarcoid after initiation of infliximab treatment, but results at post-treatment were inconclusive. Infliximab treatment was well tolerated. [14]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!